InfuSystem receives late filing notice for its 2023 annual report from NYSE

InfuSystem has received notice from the NYSE Regulation stating that the company is not in compliance with continued listing standards because the company failed to timely file its Annual Report on Form 10-K for the year 2023 due to be filed with the SEC no later than April 1, 2024. The vompany has been unable to file the Delinquent Report because the company requires additional time to complete its procedures to evaluate potential errors related to the classification of certain expenses included in general and administrative costs that should have been included in cost of sales, and the adoption and ongoing application of ASC 842. The vompany will have six months from the date of the Filing Delinquency to file the Delinquent Report with the SEC. If the company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence. The company intends to regain compliance with the Exchange’s continued listing standards.